Premium
Surgical, Oncological, and Functional Outcomes of Transoral Robotic Supraglottic Laryngectomy
Author(s) -
Hans Stéphane,
ChekkouryIdrissi Younès,
Circiu Marta P.,
Distinguin Léa,
CrevierBuchman Lise,
Lechien Jérôme R.
Publication year - 2021
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.28926
Subject(s) - medicine , transoral robotic surgery , laryngectomy , tracheotomy , surgery , neck dissection , transoral laser microsurgery , blood loss , radiation therapy , larynx , carcinoma
Objectives/Hypothesis To investigate the surgical, oncological, and functional outcomes of transoral robotic surgery (TORS) for the treatment of supraglottic squamous cell carcinoma. Study Design Retrospective chart review. Methods The charts of patients treated by TORS supraglottic laryngectomy (SGL) in an academic medical center were reviewed. The following outcomes were studied according to the tumor location: average robotic setup and operative times, mean estimated blood loss, postoperative complications, need of tracheotomy, refeeding characteristics, mean hospital stay, need of neck dissection and adjuvant therapy, 5‐year local and regional controls, overall survival (OS), and disease‐free survival (DFS). Results Seventy‐five patients underwent TORS SGL. Tumors were classified as cT1 (32%), cT2 (52%), and cT3 (16%). Average robotic setup and operative times and the mean estimated blood loss were 15 minutes, 55 minutes, and 20 mL, respectively. The mean follow‐up period ranged from 2 to 5 years. The 5‐year OS and DFS were 80.2% and 94.3%, respectively. Overall, 34.6% of patients received adjuvant radiotherapy. The majority of patients (92%) restarted an oral diet within 24 to 48 hours postsurgery. Transient tracheotomy was performed in 8% of patients. Postoperative hemorrhages occurred in 12 patients (16.0%), lengthening the hospital stay (mean = 6.8 days). There were no outcome differences regarding the tumor location. Conclusions TORS is an effective and safe therapeutic approach for early‐ and intermediate‐stages cancers. Oncological outcomes may be quite similar to other surgical approaches, including transoral laser and open surgeries. Future randomized controlled studies are needed for comparing TORS SGL with other surgical procedures. Level of Evidence 4 Laryngoscope , 131:1060–1065, 2021